# Retinoblastoma Phase II Expanded Access Clinical Trial

> **NCT06679634** · PHASE2 · RECRUITING · sponsor: **Targeted Therapy Technologies, LLC** · enrollment: 30 (estimated)

## Conditions studied

- Retinoblastoma

## Interventions

- **DRUG:** Chemoplaque also referred to as Episcleral Topotecan

## Key facts

- **NCT ID:** NCT06679634
- **Lead sponsor:** Targeted Therapy Technologies, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-21
- **Primary completion:** 2028-11
- **Final completion:** 2028-11
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06679634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06679634, "Retinoblastoma Phase II Expanded Access Clinical Trial". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06679634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*